Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Empance
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Empance is a branded generic formulation of empagliflozin, developed and manufactured by the Turkish pharmaceutical company Biofarma. It is an oral small molecule inhibitor of the sodium/glucose cotransporter 2 (SGLT2), which is primarily expressed in the proximal renal tubules of the kidneys. By blocking SGLT2, Empance inhibits the reabsorption of filtered glucose back into the bloodstream, promoting its excretion through the urine (glucosuria) and thereby lowering blood glucose levels in an insulin-independent manner. Empance is approved for the management of type 2 diabetes mellitus, either as monotherapy or in combination with other glucose-lowering agents such as metformin.
- Brand names
- Empance
- Other names
- empagliflozin
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)SLC5A1 (Sodium Glucose Cotransporter 1)
Beyond the preview
Go deeper on Empance.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Empance.